Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
scPharmaceuticals Inc (SCPH)
NASDAQ:SCPH
Holding SCPH?
Track your performance easily
SCPH Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.08 - $6.54
Previous CloseN/A
Volume61.66K
Average Volume (3M)430.97K
Market Cap
$171.14M
Enterprise Value$173.32M
Total Cash (Recent Filing)$39.28M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.27
Next Earnings
Mar 19, 2025EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.91
Shares Outstanding50,040,134
10 Day Avg. Volume282,582
30 Day Avg. Volume430,970
Standard Deviation0.17
R-Squared0.00108
Alpha0.00459
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)5.65
Price to Cash Flow (P/CF)-2.50
P/FCF Ratio0.00
Enterprise Value/Market Cap1.01
Enterprise Value/Revenue5.72
Enterprise Value/Gross Profit17.72
Enterprise Value/Ebitda-3.06
Forecast
1Y Price Target
$19.00Price Target Upside479.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
scPharmaceuticals News
PremiumCompany Announcements
scPharmaceuticals Reports Strong Growth in Q3 2024
Bulls Say, Bears Say
Bulls Say
Indication Expansion PotentialThe potential indication expansion in chronic kidney disease, if approved, could be a significant positive factor for Furoscix.
Medicare Part D OptimizationPositive effects of the Medicare Part D redesign are expected to lower patient copays and beneficially offset higher gross-to-net dynamics via higher volumes.
Salesforce ExpansionThe expanded Furoscix salesforce is expected to positively impact prescribing and awareness, with approximately 90 total representatives.
Bears Say
Demand ChallengesThe 'donut hole' issue negatively impacted Furoscix's 3Q results, lowering demand compared to expectations.
Revenue ImpactRevenues for Furoscix were affected by higher gross-to-net from lagging CMS reporting on coverage gap rebates.
Stock PerformanceShares are trading down approximately 13% due to lower than expected revenue, largely caused by Medicare coverage gap patients not filling prescriptions.
---
Ownership Overview
21.29% Insiders
6.44% Mutual Funds
0.10% Other Institutional Investors
65.76% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SCPH FAQ
What was scPharmaceuticals Inc’s price range in the past 12 months?
scPharmaceuticals Inc lowest stock price was $3.08 and its highest was $6.54 in the past 12 months.
What is scPharmaceuticals Inc’s market cap?
scPharmaceuticals Inc’s market cap is $171.14M.
When is scPharmaceuticals Inc’s upcoming earnings report date?
scPharmaceuticals Inc’s upcoming earnings report date is Mar 19, 2025 which is in 60 days.
How were scPharmaceuticals Inc’s earnings last quarter?
scPharmaceuticals Inc released its earnings results on Nov 13, 2024. The company reported -$0.75 earnings per share for the quarter, missing the consensus estimate of -$0.298 by -$0.452.
Is scPharmaceuticals Inc overvalued?
According to Wall Street analysts scPharmaceuticals Inc’s price is currently Undervalued.
Does scPharmaceuticals Inc pay dividends?
scPharmaceuticals Inc does not currently pay dividends.
What is scPharmaceuticals Inc’s EPS estimate?
scPharmaceuticals Inc’s EPS estimate is -0.38.
How many shares outstanding does scPharmaceuticals Inc have?
scPharmaceuticals Inc has 50,040,134 shares outstanding.
What happened to scPharmaceuticals Inc’s price movement after its last earnings report?
scPharmaceuticals Inc reported an EPS of -$0.75 in its last earnings report, missing expectations of -$0.298. Following the earnings report the stock price went down -14.066%.
Which hedge fund is a major shareholder of scPharmaceuticals Inc?
Among the largest hedge funds holding scPharmaceuticals Inc’s share is Woodline Partners LP. It holds scPharmaceuticals Inc’s shares valued at 2M.
---
scPharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.00 (479.27% Upside)
$19.00 (479.27% Upside)
Blogger Sentiment
Bullish
SCPH Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 501.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 3.9%
Last 30 Days ▼ 3.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-43.15%
12-Months-Change
Fundamentals
Return on Equity
-200.65%
Trailing 12-Months
Asset Growth
17.88%
Trailing 12-Months
Company Description
scPharmaceuticals Inc
scPharmaceuticals, Inc.engages in the development of transformative pharmaceutical products for subcutaneous delivery. Its products include furosemide, used as parenteral diuretic in treating heart failure and ceftriaxone, used as parenteral antibiotic outside the hospital setting. The company was founded by Pieter Muntendam and Bertram Pitt in February 2013 and is headquartered in Burlington, MA.
---
SCPH Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a positive overall sentiment driven by significant revenue growth, strategic expansions, and successful financing, despite some challenges with higher discounts and increased net loss.Read More>---
SCPH Stock 12 Month Forecast
Average Price Target
$19.00
▲(479.27% Upside)
Technical Analysis
Evolus
―
Kiniksa Pharmaceuticals
―
EyePoint Pharmaceuticals
―
Clearside Biomedical
―
Rigel
―
Xeris Pharmaceuticals
―
Best Analysts Covering SCPH
1 Year
1 Year Success Rate
7/18 ratings generated profit
1 Year Average Return
-2.95%
reiterated a buy rating 2 months ago
Copying Douglas Tsao's trades and holding each position for 1 Year would result in 38.89% of your transactions generating a profit, with an average return of -2.95% per trade.
---